Genflow Bio Accelerates Development of Antiaging Gene Therapy Platform with €250K Grant

Genflow Bio wins EUR 250k to accelerate antiaging genetic therapy platform
Genflow announced that it has received a nondilutive grant of EUR250,000 for its adenoassociated virus (AAV), research and development program in Estonia from the Applied Research Programme of Enterprise Estonia. This Estonian governmental organization is designed to encourage business growth.

Longevity. Longevity.

This R&D project is a collaboration between Genflow, an Estonian biotech company that specialises in research and development, and IVEX Lab OU.


Genflow Bio scoops €250k to accelerate antiaging gene therapy platform

Leave a Reply

Your email address will not be published. Required fields are marked *